

PROMOTION RECOMMENDATION
THE UNIVERSITY OF MICHIGAN
MEDICAL SCHOOL
DEPARTMENT OF UROLOGY

Ganesh S. Palapattu, M.D., associate professor of urology, with tenure, Department of Urology, Medical School, is recommended for promotion to professor of urology, with tenure, Department of Urology, Medical School.

Academic Degrees:

M.D.	1997	Baylor College of Medicine, Houston, Texas
B.A.	1992	University of Texas, Austin, Texas

Professional Record:

2012-present	Associate Professor of Urology, University of Michigan
2011-2012	Associate Professor of Clinical Urology, The Methodist Hospital, Weill Cornell Medical College, Houston, Texas
2009-2011	Associate Member, The Methodist Hospital Research Institute, Houston, Texas
2007-2009	Assistant Professor of Pathology and Laboratory Medicine, University of Rochester
2007-2009	Assistant Professor of Oncology, University of Rochester
2005-2009	Assistant Professor of Urology, University of Rochester
2003-2005	Clinical Instructor, James Buchanan Brady Urological Institute, Johns Hopkins University

Summary of Evaluation:

Teaching: Dr. Palapattu has dedicated around 20% of his effort to teaching and educational activities. He is involved in the education of M3 and M4 students, residents, fellows, post-graduate students, and practicing physicians. Dr. Palapattu estimates spending 800 hours per year providing direct education to residents and fellows in the clinic, operating room, in-patient rounds, and clinical conferences. For the post-graduate trainees, Dr. Palapattu assembled a team and designed a curriculum for an NIH T32 training grant in urologic oncology. He has given talks locally, nationally, and internationally and has lectured the past two years on prostate cancer for the American Urological Association (AUA) Basic Science Review Course. He conceived, planned, and organized the Magnetic Resonance Ultrasound Fusion Biopsy Course at the University of Michigan which provided hands-on training to regional practicing urologists. Dr. Palapattu coordinates the weekly GU Multi-disciplinary Tumor Board conference for clinicians who manage and treat patients with urologic cancers.

Research: Dr. Palapattu is a translational scientist and spends 50% of his effort on research on the evaluation and management of men with high risk prostate cancer in collaboration with scientists and clinicians at the University of Michigan. In his lab, Dr. Palapattu and his team

focus on studying prostate cancer metabolism strategies coupled with bioinformatics and molecular biology as well as developing new diagnostic and therapeutic strategies. Dr. Palapattu has produced 88 peer-reviewed publications, four book chapters, and 49 abstracts. He has served as an ad hoc reviewer for 16 journals and currently for seven. He serves on the editorial board for the Basic/Translational Science Survey Review Board of Urologic Oncology: Seminars and Original Investigations. He is a co-inventor on five submitted patents. Dr. Palapattu is well-funded and is currently a principal investigator on three active grants (1 NCI/NIH, 1 NIH-DHHS-US, and 1 Prostate Cancer Foundation) as well as a co-principal investigator on three grants, and co-investigator on two grants.

Recent and Significant Publications:

Khan AP, Rajendiran TM, Ateeq B, Asangani IA, Athanikar JN, Yocum AK, Mehra R, Siddiqui J, Palapattu G, Wei JT, Michailidis G, Sreekumar A, Chinnaiyan AM: The role of sarcosine metabolism in prostate cancer progression. *Neoplasia* 15:491-501, 2013.

Sanchez C, Chan R, Bajgain P, Rambally S, Palapattu G, Mims M, Rooney CM, Leen AM, Brenner MK, Vera JF: Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer. *Prostate cancer and prostatic diseases* 16:123-131, 2013.

Kaushik AK, Vareed SK, Basu S, Putluri V, Putluri N, Panzitt K, Brennan CA, Chinnaiyan AM, Vergara IA, Erho N, Weigel NL, Mitsiades N, Shojaie A, Palapattu G, Michailidis G, Sreekumar A: Metabolomic profiling identifies biochemical pathways associated with castration-resistant prostate cancer. *Journal of Proteome Research* 13:1088-1100, 2014.

Ferrati S, Nicolov E, Bansal S, Zabre E, Geninatti T, Ziemys A, Hudson L, Ferrari M, Goodall R, Khera M, Palapattu G, Grattoni A: Delivering enhanced testosterone replacement therapy through nanochannels. *Advanced healthcare materials* 4:446-451, 2015.

Zaslavsky AB, Gloeckner-Kalousek A, Adams M, Putluri N, Venghatakrishnan H, Li H, Morgan TM, Feng FY, Tewari M, Sreekumar A, Palapattu GS: Platelet synthesized testosterone in men with prostate cancer induces androgen receptor signaling. *Neoplasia* 17:490-496, 2015.

Service: Dr. Palapattu is a member of the American Urological Association, Indian American Urological Association, Johns Hopkins Medical and Surgical Association, Southwest Oncology Group, Society of Urologic Oncology, American Society of Clinical Oncology, and Urology Research Society. Nationally, he serves as a co-chair of the SWOG Study S0931 and the nominating committee of the Society Urologic Oncology. In the Department of Urology, Dr. Palapattu serves as chief of the Division of Urology Oncology and a member of the Graduation Education Committee, Senior Clinical Management, and Clinical Competency Committee. In the Comprehensive Cancer Center, he serves as a member of the Cancer Research Committee, Executive Committee, and Senior Clinical Leadership as well as co-lead of the Prostate Cancer Program.

Dr. Palapattu is the go-to urologic oncologist. He sees patients with high risk prostate cancer and performs robotic prostatectomy and nerve-sparing surgical techniques. For patients with kidney cancer, he manages open and minimally invasive surgical approaches for small and large renal masses with vascular involvement as well as for patients with testis cancer, he performs open retroperitoneal lymph node dissection for large post-chemotherapy residual masses. He is a surgeon-scientist with great skills as a superlative teacher and mentor.

External Reviewers:

Reviewer A: “Few urologists have the special skill sets of Dr. Palapattu. Not only is he a respected clinician and surgeon, he also is one of an increasingly rare breed of urologists who understand and carry out science at a high level....In the last few years he has been recognized as one of the thought leaders in the management of high risk localized prostate cancers and has been an invited speaker and panel member at national and international meetings to discuss this topic....He has received highly competitive funding to investigate the metabolomics of prostate cancer, with a focus on aggressive and metastatic prostate cancer, and has published several highly cited articles that are well known in the prostate cancer field.”

Reviewer B: “He is a nationally and internationally renowned surgeon with special expertise in robotic assisted laparoscopic surgery....He was selected as an ‘AUA Rising Star’ in Urology due to his promise in the field of basic research, and he has not disappointed.”

Reviewer C: “Over the past several years he has established a national and internationally respected program in CRPC in addition to assuming increased administrative and education responsibilities....He is one of the few true physician-researchers left in the field that is able to generate competitive funding from his laboratory, but also function clinically.”


Reviewer D: “He is the PI of an advanced Training in Urology T32 grant that runs through 2018...He has mentored a spectrum of trainees from medical students, house officers, post-doctoral fellows and faculty members. Evidence of this mentorship is reflected in his senior authorship publications with his trainees as first authors.”

Reviewer E: “Dr. Palapattu is a translational physician scientist, a relatively rare phenotype in the field of urology. He is certainly as accomplished and holds as much promise as any in his generation. I suspect if he continues on his current trajectory, he will be on the short lists for leadership (Chair) positions in the next 5-10 years. I would place him in the top ten nationally as a urological translational physician scientist.”

Reviewer F: “It is not easy to be a first rate clinician and researcher simultaneously but Dr. Palapattu is undoubtedly a standout in both areas. He has made significant basic science discoveries related to prostate cancer carcinogenesis. He has an active and funded research laboratory with peer-reviewed funding from the NIH, the Department of Defense, and the Prostate Cancer Foundation.”

Summary of Recommendation:

Dr. Palapattu is an excellent clinician, educator, citizen, and translational researcher in the Department of Urology. He is an international leader in urologic oncology and a great mentor. I wholeheartedly recommend Ganesh S. Palapattu, M.D. for promotion to professor of urology, with Tenure, Department of Urology, Medical School.



Marschall S. Runge, M.D., Ph.D.
Executive Vice President for Medical Affairs
Dean, Medical School

May 2016